MCL1 and cancer: As USP9X inhibition has been linked to apoptosis and prevention of drug resistance in malignancies through Mcl-1 degradation, WP1130 is thought to target a Bcr-Abl-/Mcl-1-specific pathway as a USP inhibitor, suggesting a capacity for cancer treatment [148,149].